TB-500 is a fragment of Thymosin Beta-4, working primarily through actin regulation and cell migration, with strong support for skin wound healing and cardiac tissue
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
Dear Marci, My doctor and I have been discussing some of the new GLP-1 weight loss medications
To successfully employ an all-comers strategy moving forward, manufacturers need to ensure products have strong clinical and/or non-clinical differentiation, a robust data package that addresses a range of patient types and comorbidities, and well-funded physician and patient facing marketing campaigns
In ALS, cytosolic TDP-43 elicits innate immune responses through mitochondrial damage and activation of the cGAS/STING pathway (Ma et al., 2024
